DiaMedica TherapeuticsDMAC +1.75%31 PEG Ratio is 0.00 as of Jun. 24, 2026. GuruFocus rates DMAC with a GF Score™ of 31/100. The stock has 1 warning sign investors should review. Among 95 Biotechnology companies, DiaMedica Therapeutics ranks worse than 1052630.53% on this metric.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for DiaMedica Therapeutics's PEG Ratio or its related term are showing as below:
DMAC's PEG Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 1.91 * Ranked among companies with meaningful PEG Ratio only.
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
DiaMedica Therapeutics (NAS:DMAC) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, DiaMedica Therapeutics's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DiaMedica Therapeutics PEG Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, DiaMedica Therapeutics's PEG Ratio distribution charts can be found below:
* The bar in red indicates where DiaMedica Therapeutics's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
DiaMedica Therapeutics (DMAC) has a PEG Ratio of 0.00 as of Jun. 24, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on DiaMedica Therapeutics and its competitors. According to the industry distribution chart, DiaMedica Therapeutics ranks #999999 out of 95 companies in the Biotechnology industry.
Is DiaMedica Therapeutics' PEG Ratio too high?
DiaMedica Therapeutics' current PEG Ratio is 0.00. Based on the distribution chart, DiaMedica Therapeutics ranks #999999 out of 95 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, DiaMedica Therapeutics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does DiaMedica Therapeutics' PEG Ratio compare to BCYC and RZLT?
According to the Biotechnology industry distribution chart, DiaMedica Therapeutics ranks #999999 out of 95 companies for PEG Ratio. This places DiaMedica Therapeutics in the lower half of its industry. The industry median PEG Ratio is 1.91. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Biotechnology company?
The median PEG Ratio among Biotechnology companies is 1.91, based on 95 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on DiaMedica Therapeutics and its competitors. For the Biotechnology industry, the median PEG Ratio is 1.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DiaMedica Therapeutics's current PEG Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DiaMedica Therapeutics stock overvalued right now?
DiaMedica Therapeutics (DMAC) has a current PEG Ratio of 0.00. The current PEG Ratio is 0.00. DiaMedica Therapeutics' overall GF Score™ is 31/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For DiaMedica Therapeutics (DMAC), the current PEG Ratio is 0.00 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
31GF Score
Get the complete analysis for DMAC
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DMAC has been successfully added to your 
